Yazar "Aslan, Vedat" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    A case series of CML patients who were presented with isolated thrombocytosis
    (American Society of Hematology, 2022) Karakuş, Volkan; Aslan, Vedat; Parça, Güleycan; Sevindik, Ömür Gökmen; Keklik Karadağ, Fatma; Kurtoğlu, Erdal; Saydam, Güray
    Per WHO 2016 and 2022 (5th ed.) myeloproliferative disease guidelines, Chronic Myeloid Leukemia (CML) is classified under two major groups according to the presence of bcr-abl translocation; these groups require different treatment approaches and show clinical presentation heterogeneity. Treatment agents such as tyrosine kinase inhibitors (Imatinib, Dasatinib, Nilotinib, Bosutinib, Ponatinib, Radotinib), Omacetaxine and Asciminib have been used in the treatment of Bcr abl positive CML according to the patient's clinic and mutation status. According to the IRIS study, a study evaluating CML patients treatment response to imatinib, the major molecular response was 33.3% at 3 months, the major molecular response was 48% at 6 months, and the major molecular response was 62.1% at 12 months; furthermore, the rate of achieving a complete molecular response at 12 months was 94.9% (4). In patients who was treated with imatinib as first line therapy, the rate of transformation to accelerated or blastic phase at 18 months was 0.9% in the MMR group and 9.9% in the non-MMR group. In "conventional" CML patients, high leukocyte counts may be accompanied by thrombocytosis; though presentation with only thrombocytosis without leukocytosis is hardly described so far. In this poster presentation, we introduced 7 cases who initially presented with isolated thrombocytosis and then diagnosed with Ph(+) CML. This study was conducted in three adult hematology centers from Antalya, Izmir and Istanbul. 400 patients followed in these centers were reviewed retrospectively; seven patients presented with isolated thrombocytosis were identified. Demographic characteristics, diagnostic findings, and risk scores of these patients were evaluated (Tablo 1). Eln 2013 response criteria were used for evaluation of response for 3rd, 6th, 12th. monthly responses (Figure 1). Here we present 7 CML patients without leukocytosis who were diagnosed with marked thrombocytosis. The patients had similar symptoms and physical examination with no obvious splenomegaly or thrombosis. All of the patients had minimal basophilia and normal peripheral smear findings. All patients responded well to imatinib therapy. During follow up patients who maintained their MMR achieve had a better clinical course and prognosis compared to other CML patients.
  • Küçük Resim
    Öğe
    Demographics of patients with heart failure who were over 80 years old and were admitted to the cardiology clinics in Turkey
    (Turkish Society of Cardiology, 2019) Gök, Gülay; Zoghi, Mehdi; Sinan, Ümit Yaşar; Kılıç, Salih; Tokgözoğlu, Lale; Sümerkan, Mutlu Çağan; Emren, Volkan; Bekar, Lütfü; Cerşit, Sinan; Tunç, Elif; Ulucan, Şeref; Altuntaş, Emine; Canpolat, Uğur; Özmen, Namık; Açıksarı, Gönül; Doğan, Nazile Bilgin; Günay, Şeyda; Kemaloğlu, Meltem Didem; Nacar, Alper Buğra; Karakoyun, Süleyman; İnci, Sinan; Özlek, Bülent; Aslan, Onur; Baykız, Derya; Gündüz, Sabahattin; Köroğlu, Sedat; Helvacı, Ayşen; Coşkun, Raşit; Yüksel, İsa Öner; Çetin, Şükrü; Yesin, Mahmut; Gürsoy, Mustafa Ozan; Çatırlı Enar, Sibel; Tek Öztürk, Müjgan; Yılmaz, Aykut; Başaran, Özcan; Okyay, Kaan; Öztürk, Cengiz; Çelik, Oğuzhan; Yalçınkaya, Emre; Aslan, Vedat; Şenol, Utku; Uçar, Fatih Mehmet; Kozluca, Volkan; Türkoğlu, Ebru İpek; Şekuri, Cevat; Ertürk, Mehmet; Altun, İbrahim; Belen, Erdal; Aksan, Gökhan; Yıldırım, Erkan; Sayın, Ahmet; Akkoyun, Dursun Çayan; Tunçez, Abdullah; Doğan, Volkan; Gürel, Yusuf Emre; Demirelli, Selami; Koca, Çiğdem; Biteker, Murat; Bas, Hasan Aydın; Güzet, Feza; Taçoy, Gülten; Alpsoy, Şeref; Turan, Turhan; Davutoğlu, Vedat; Birdane, Alparslan; Onrat, Ersel; Baha, Mehmet Reşat; Yılmaz, Sabiye; Altay, Servet; Alıcı, Mehmet Hayri; Özcan, İsmail Türkay; Kuş, Görkem; Demir, Gültekin Günhan; Sancar, Kadriye Memiç; Demirçelik, Muhammed Bora; Yanık, Ahmet; Akciğer, Atike Nazlı; Hoşcan, Yeşim; Arslan, Kürşat; Otlu, Yılmaz Ömür; Şahin, İsmail; Ersoy, İbrahim; YIlmaz, Dilek Çiçek; Mert, Kadir Uğur; Varim, Perihan; Arı, Hatem
    Objective: Heart failure (HF) has a high prevalence and mortality rate in elderly patients; however, there are few studies that have focused on patients older than 80 years. The aim of this study is to describe and compare the age-specific demographics and clinical features of Turkish elderly patients with HF who were admitted to cardiology clinics. Methods: The Epidemiology of Cardiovascular Disease in Elderly Turkish population (ELDER-TURK) study was conducted in 73 centers in Turkey, and it recruited a total of 5694 patients aged 65 years or older. In this study, the clinical profile of the patients who were aged 80 years or older and those between 65 and 79 years with HF were described and compared based on the ejection fraction (EF)-related classification: HFrEF and HFpEF (is considered as EF:>= 50%). Results: A total of 1098 patients (male, 47.5%; mean age, 83.5 +/- 3.1 years) aged 80 years and 4596 patients (male, 50.2 %; mean age, 71.1 +/- 4.31 years) aged 65-79 years were enrolled in this study. The prevalence of HF was 39.8% for patients who were>= 80 years and 27.1% for patients 65-79 years old. For patients aged>= 80 years with HF, the prevalence rate was 67% for hypertension (HT), 25.6% for diabetes mellitus (DM), 54.3% for coronary artery disease (CAD), and 42.3% for atrial fibrilation. Female proportion was lower in the HFrEF group (p=0.019). The prevalence of HT and DM was higher in the HFpEF group (p<0.01), whereas CAD had a higher prevalence in the HFrEF group (p=0.02). Among patients aged 65-79 years, 43.9% (548) had HFpEF, and 56.1% (700) had HFrEF. In this group of patients aged 65-79 years with HFrEF, the prevalence of DM was significantly higher than in patients aged>= 80 years with HFrEF (p<0.01). Conclusion: HF is common in elderly Turkish population, and its frequency increases significantly with age. Females, diabetics, and hypertensives are more likely to have HFpEF, whereas CAD patients are more likely to have HFrEF.